Topic: Kidney Cancer

Recent Advances for Renal Cell Carcinoma: A 2018 Review

Erik P. Castle, MD, highlights recent advances in surgery, individualized medicines, and immunotherapies for patients with renal cell carcinoma (RCC). He reviews updates in genetic sequencing and CAR-T cell therapy, as well as developing role of cancer-associated macrophage-like cells (CAMLs), in these patients.

Read More

Adjuvant Therapy in High Risk Renal Cell Carcinoma

Alan H. Bryce, MD, surveys data from three phase III trials on adjuvant therapies for high-risk renal cell carcinoma. He discusses the controversies following the conclusions of the completed trials and emphasizes the need for research in further adjuvant therapies beyond those that target the VEGF pathway.

Read More

Why Should a Clinician Care About 3D Printing, VR Simulators and Genetically Engineered Animal Models for Kidney Cancer?

Richard E. Link, MD, PhD, discusses current challenges in the management of renal cell carcinoma (RCC), as well as research efforts to address these challenges. He specifically reviews 3D-printed models and virtual reality simulation for pre-surgical rehearsal and training, and an engineered animal model for identifying genetic targets in papillary RCC.

Read More

Cytoreductive Surgery in the Era of Targeted Therapy for Kidney Cancer: If Yes, When?

Riccardo Autorino MD, PhD, FEBU, discusses the decline in using cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) due to the shift toward targeted therapy in urological practice. He explains the rationale behind CN, its drawbacks, and individual scenarios in which it could provide a benefit, as opposed to targeted therapy and nephron-sparing surgery (NSS). Furthermore, he presents the current therapeutic algorithm for patient selection in these treatment options.

Read More

MRI Fusion Biopsy

Peter Schulam, MD, PhD, reviews the controversy surrounding prostate cancer screening, explains the literature that led to the United States Preventive Services Task Force (USPSTF) coming out with a C recommendation for prostate cancer screening, and notes the limitations in the current standard of transrectal ultrasound (TRUS) biopsy. He then discusses how MRI fusion biopsy could address these limitations.

Read More
Loading

Join the GRU Community

- Why Join? -